Zovighian Bernard J sold 9,184 shares of Edwards Lifesciences Corp at $103.39 for −$949k on Nov 9, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
CEO
CEO
Filed Nov 9, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$949,488.76Shares × reported price
Shares traded
9,184Common Stock
Price per share
$103.39Reported price. Read footnotes for ranges.
% of reported position traded
7.53%This security and ownership context
Holdings after
112,761Direct
Trade date
Nov 9, 2026Sell
Filed
Nov 9, 2026, 4:29 PM ET0-day reporting delay
Accession
0001225208-26-008780Code S · Transaction 395954
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 121,945 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 9, 2026Sell13,916$102.78−$1,430,290.65Trade 395955
Nov 9, 2026Option exercise23,100$0.00$0Trade 395956
Nov 9, 2026Option exercise23,100$72.68$1,678,908Trade 395953
4 transaction rows in this filing. Joint filers share the same rows.

EW price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
EW · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 16, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −17%1w ago −8.7%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 28, 2026. F2: This transaction was executed in multiple trades at prices ranging from $103.18 to $103.66 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3: This transaction was executed in multiple trades at prices ranging from $102.17 to $103.16 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F4: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.